I want to donate

The Neurodegeneration and Neuroimflammation group’s mission is to work in a multidisciplinary, coordinated and translational way to increase knowledge of neurodegenerative and neuroinflammatory diseases to respond to the needs and demands of those suffering from them and their families.

Main lines of research

Clinical-care priority lines:

  • Study of neuropsychological alterations and cognitive rehabilitation in multiple sclerosis.
  • Study of the emotional impact, coping and adaptation to the diagnosis of multiple sclerosis.
  • Improvement of the adherence to immunomodulatory treatment in multiple sclerosis.
  • Use of a multi-parametric, multi-user and multi-functional database for multiple sclerosis.
  • Implementation of the use of electronic devices to assess disability in patients with multiple sclerosis.
  • Application of new cranial MR techniques as prognosis markers in multiple sclerosis.
  • Computer assisted systematization of lesions seen on cranial MRIs in patients with multiple sclerosis.
  • Application and integration of information technologies in assistance activity and research in multiple sclerosis.
  • Treatment of orphans in hereditary ataxia.


Priority lines in basic research:

  • Study of the profiles of specific miRNAs for different clinical forms and progressions of multiple sclerosis.
  • Study of the DNA methylation profile of patients with multiple sclerosis.
  • Study of the molecular mechanisms associated to neurodegeneration.
  • Study of the progression of cognitive function biomarkers in patients with multiple sclerosis.
  • Determination of biological factors (genetic and biochemical) in response to immunomodulatory treatments in multiple sclerosis.
  • Study of the intestinal microbes in Parkinson’s disease and other neurodegenerative diseases.
  • Bank of DNA, CSF, and serum samples for neuroimmunology diseases.
Strategic objectives
  • To be the reference group in the province of Girona in research and teaching in multiple sclerosis and other diseases
  • To have a national and international presence in the area of research in multiple sclerosis
  • To consolidate clinical research into multiple sclerosis
  • To consolidate basic research into multiple sclerosis
  • To promote and lead research into new treatments for multiple sclerosis
  • To begin clinical research into Parkinson’s disease and other movement disorders
  • To begin clinical research into Alzheimer’s and other dementias
  • To consolidate clinical research into hereditary ataxia
  • To lead research into neuropsychology of multiple sclerosis on a national level
  • To establishing research collaborations with other national and international groups for multiple sclerosis
  • To promote research into multiple sclerosis in nursing and neuropsychology
  • To promote training and teaching in multiple sclerosis, Parkinson’s disease, hereditary ataxia and dementias for health professionals, specialists and affected patients and relatives alike
  • Technological innovation in multiple sclerosis and other neurodegenerative diseases

Contreras-Rodriguez O, Arnoriaga-Rodríguez M, Miranda-Olivos R, Blasco G, Biarnés C, Puig J, Rivera-Pinto J, Calle ML, Pérez-Brocal V, Moya A, Coll C, Ramió-Torrentà L, Soriano-Mas C, Fernandez-Real JM

Obesity status and obesity-associated gut dysbiosis effects on hypothalamic structural covariance.


Álvarez Bravo G, Sánchez Cirera L, Angerri Nadal M, Ramió I Torrentà L

Clinical heterogeneity in patients with myoclonus associated to COVID-19.

NEUROLOGICAL SCIENCES, 2022, 43, 1587-1592

Mayneris-Perxachs J, Castells-Nobau A, Arnoriaga-Rodríguez M, Garre-Olmo J, Puig J, Ramos R, Martínez-Hernández F, Burokas A, Coll C, Moreno-Navarrete JM, Zapata-Tona C, Pedraza S, Pérez-Brocal V, Ramió-Torrentà L, Ricart W, Moya A, Martínez-García M, Maldonado R, Fernández-Real JM

Caudovirales bacteriophages are associated with improved executive function and memory in flies, mice, and humans.

CELL HOST & MICROBE, 2022, 30, 340

Sampedro F, Martínez-Horta S, Horta-Barba A, Grothe MJ, Labrador-Espinosa MA, Jesús S, Adarmes-Gómez A, Carrillo F, Puig-Davi A, Lora FR, Barberá MA, Pastor P, Arroyo SE, Vila BS, Foraster AC, Martínez JR, Padilla FC, Morlans MP, Aramburu IG, Ceberio JI, Vara JH, de Fábregues-Boixar O, de Deus Fonticoba T, Ávila A, Martínez-Castrillo JC, Bejr-Kasem H, Campolongo A, Pascual-Sedano B, Martínez-Martín P, Santos-García D, Mir P, Kulisevsky J

Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease.


Vermersch P, Brieva-Ruiz L, Fox RJ, Paul F, Ramio-Torrenta L, Schwab M, Moussy A, Mansfield C, Hermine O, Maciejowski M, AB07002 Study Group

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.


Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group.


Parkinson's Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up.


Zabalza A, Arrambide G, Otero-Romero S, Pappolla A, Tagliani P, López-Maza S, Cárdenas-Robledo S, Esperalba J, Fernández-Naval C, Martínez-Gallo M, Castillo M, Bonastre M, Resina-Salles M, Bertran J, Rodriguez-Barranco M, Carbonell-Mirabent P, Gonzalez M, Merchan M, Quiroga-Varela A, Miguela A, Gómez I, Álvarez G, Robles R, Perez Del Campo D, Queralt X, Soler MJ, Agraz I, Martinez-Valle F, Rodríguez-Acevedo B, Midaglia L, Vidal-Jordana Á, Cobo-Calvo Á, Tur C, Galan I, Castillo J, Río J, Espejo C, Comabella M, Nos C, Sastre-Garriga J, Ramió-Torrentà L, Tintoré M, Montalban X

Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?


Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson's Disease Patients: A 2-Year Follow-Up Study.

Diagnostics, 2022, 12
Competitive projects
Codi oficial: Estudio de biomarcadores moleculares neurodegeneración Start date:01/01/2022 Data fi: 31/12/2023 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ Organisme finançador: FRANCISCO SORIA MELGUIZO, S.A Ajuda: 325,600 €
Codi oficial: FA-calcitriol (ATAXIES) Start date:02/12/2020 Data fi: 02/12/2022 Investigador/a principal: BERTA ALEMANY PERNA Organisme finançador: FEDERACIÓN DE ATAXIAS DE ESPAÑA Ajuda: 6,000 €
Codi oficial: EME-REEM 2020 Start date:01/07/2020 Data fi: 31/12/2022 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ Organisme finançador: ASOC. ESCLEROSIS MULTIPLE ESPAÑA Ajuda: 40,000 €
Codi oficial: RD21/0002/0063 - EM Start date:01/01/2022 Data fi: 31/12/2024 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 136,744.30 €
Clinical Guidelines

Guies mèdiques de la Societat Catalana de Neurologia: Diagnòstic i tractament de l’Esclerosi Múltiple. Societat Catalana de Neurologia.
Autors: Lluís Ramió-Torrentà, René Robles, Gary Alvarez, etc. 2020

Merchan-Ruiz M, González-del-Rio M, Ramió-Torrentà L, Del Olmo M, Vilalta T. Guia Sala de tractaments UNIEM-TG. Institut
d'Assistència Sanitària. 2020

Job offers


If you are a researcher and you are interested in collaborating with any of our research groups, please fill in this form.
I am interested in
If you are a student or you want to do an internship with any of our research groups, please fill in this form.
I am interested in